Comparative Pharmacokinetics and Safety of Cannabidiol in a Powder Formulation, CBtru<sup>®</sup>, vs an Oil-Based Formulation, Epidyolex<sup>®</sup>, Under Fasted and Fed Conditions in Healthy Participants: A Randomized Open-Label Cross-Over Phase I Study.

CNS Drugs · 2026 · PMC13095987 · PMID 41888503

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the values were numerically higher for TP than for RP, the differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Comparative Pharmacokinetics and Safety of Cannabidiol in a Powder Formulation, CBtru&lt;sup&gt;®&lt;/sup&gt;, vs an Oil-Based Formulation, Epidyolex&lt;sup&gt;®&lt;/sup&gt;, Under Fasted and Fed Conditions in Healthy Participants: A Randomized Open-Label Cross-Over Phase I Study.

The sentences

Comparative Pharmacokinetics and Safety of Cannabidiol in a Powder Formulation, CBtru<sup>®</sup>, vs an Oil-Based Formulation, Epidyolex<sup>®</sup>, Under Fasted and Fed Conditions in Healthy Participants: A Randomized Open-Label Cross-Over Phase I Study.